TY - JOUR T1 - Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model JF - Anticancer Research JO - Anticancer Res SP - 5999 LP - 6005 DO - 10.21873/anticanres.13805 VL - 39 IS - 11 AU - GUANGWEI ZHU AU - MING ZHAO AU - QINGHONG HAN AU - YUYING TAN AU - YU SUN AU - MICHAEL BOUVET AU - SHREE RAM SINGH AU - JIANXIN YE AU - ROBERT M. HOFFMAN Y1 - 2019/11/01 UR - http://ar.iiarjournals.org/content/39/11/5999.abstract N2 - Background/Aim: In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model. Materials and Methods: A patient CRC tumor previously established in nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice. Harvested tumor fragments were transplanted orthotopically in non-transgenic nude mice. Mice were randomized into three groups: Group 1 (G1), untreated-control; Group 2 (G2), OXA+5-FU; Group 3 (G3), TRAB+OXA+5-FU. Tumor width, length, and mouse body weight were measured twice a week. Results: Both treatment groups inhibited tumor growth compared to the untreated control group. The combination of TRAB, OXA and 5-FU was significantly more efficacious than OXA+5-FU and arrested tumor growth. No significant changes were observed in body-weight in any of the three groups. Conclusion: TRAB, OXA and 5-FU combination has clinical potential for this and other CRC patients. ER -